CAR-Macrophage Cell Therapy — PatSnap Eureka
CAR-Macrophage & TAM Polarization Cell Therapy Pipeline
Tumor-associated macrophages constitute up to 50% of the cellular mass within solid tumor microenvironments. Two convergent strategies — CAR-macrophage engineering and M2-to-M1 repolarization — are redefining how the immune system can be recruited against solid tumors.
TAM Composition in Solid Tumors
TAMs represent 30–50% of stromal cells across major solid tumor types
Why Tumor-Associated Macrophages Are a Priority Target
Retrieved results uniformly frame TAMs as the dominant immunosuppressive leukocyte population in solid tumors, constituting 30–50% of stromal cells in the tumor microenvironment (TME) across breast, prostate, ovarian, pancreatic, liver, lung, gastric, and colorectal cancers. Their M2-like phenotype — driven by cytokines including IL-4, IL-10, IL-13, and M-CSF — supports tumor cell proliferation, matrix remodeling, neo-angiogenesis, lymphangiogenesis, and T cell suppression.
According to PatSnap's life sciences intelligence platform, retrieved results consistently associate high TAM density with poor patient prognosis across multiple tumor types, making TAMs both a biomarker of disease aggressiveness and a compelling therapeutic target. The principal molecular axes addressed in this dataset include CSF1/CSF1R, IL-4Rα, TLR7/8/3/4/9, CD47/SIRPα, TAM receptor kinases (Tyro3, Axl, MerTK), c-MYC, and the metabolic regulators ACOD1 and KEAP1.
The World Health Organization estimates that cancer remains a leading cause of mortality globally, underscoring the urgency of developing effective solid tumor immunotherapies. The field of myeloid cell engineering has attracted intensifying translational focus from institutions across North America, Europe, China, and Australia, with particular density of Chinese academic medical centers.
Two convergent strategies define the innovation landscape: engineering macrophages with chimeric antigen receptors (CAR-Ms) to enable antigen-directed phagocytosis and cytotoxicity, and pharmacologically or biologically repolarizing endogenous TAMs from M2 toward tumoricidal M1 states. The PatSnap Analytics platform enables researchers to map both tracks simultaneously across patent and literature databases.
Key Data Signals from the CAR-Macrophage Pipeline
Data visualisations derived from patent and literature records retrieved via PatSnap Eureka across targeted searches in this dataset.
Therapeutic Modalities by Development Stage
Pipeline distribution across 8 identified modalities — from preclinical CAR-M engineering to clinical CD47 blockade and 606 documented TAM-targeting trials.
CAR-M Intracellular Domain Efficacy Ranking
FcRγ identified as the superior phagocytic domain; Megf10 also effective; PI3K-recruiting domains modestly enhance engulfment.
TAM-Targeting Clinical Trial Landscape (to May 2021)
606 clinical trials and 143 tested products documented; two-thirds employed macrophage-targeting therapies; most at early phase.
Key Molecular Target Axes — Citation Frequency in Dataset
CSF1R is the most frequently cited target; CD47/SIRPα, IL-4Rα, TLR7/8, and ACOD1 represent high-activity innovation nodes.
Eight Distinct Approaches to Macrophage-Based Cancer Therapy
Retrieved results document a rich pipeline spanning cell engineering, pharmacological reprogramming, and nanomedicine delivery — all targeting the immunosuppressive TAM population in solid tumors.
CAR-Macrophage (CAR-M) Cell Therapy
CAR-macrophages are engineered primary macrophages expressing chimeric antigen receptors that redirect phagocytosis and cytotoxicity toward tumor-associated antigens. The foundational mechanism — chimeric antigen receptors engineered specifically for phagocytosis (CAR-Ps) — was described at UCSF with Megf10 and FcRγ as the most effective intracellular domains. CAR-M and CAR-T cells demonstrated synergistic tumor killing in vitro.
FcRγ = most potent phagocytic domainiPSC-Derived CAR-Macrophage (CAR-iMAC) Platforms
iPSC-derived CAR-macrophages offer a scalable, off-the-shelf alternative to autologous primary CAR-M therapy. CRISPR-based metabolic reprogramming — specifically ACOD1 knockout — demonstrated enhanced persistence of pro-inflammatory polarization and superior anti-tumor efficacy in ovarian and pancreatic cancer mouse models. Research led by institutions validated across PatSnap's customer network including Zhejiang University School of Medicine.
ACOD1 KO → enhanced M1 persistenceTAM Polarization Reprogramming — TLR Agonism
TLR7/8 agonist R848 loaded into β-cyclodextrin nanoparticles (CDNP-R848) drove M1 phenotype conversion in vivo, controlled tumor growth as a monotherapy in mice, and protected against tumor rechallenge. Nanobodies conjugated to TLR7/8 agonist IMDQ targeting the macrophage mannose receptor (MMR/CD206) achieved cell-specific IMDQ delivery and reduced tumor growth in vivo. Work led by Massachusetts General Hospital and VIB Brussels.
R848 CDNP → in vivo tumor controlMetabolic Reprogramming of TAMs
Drugs targeting fatty acid oxidation (perhexiline, trimetazidine), glutaminolysis (CB-839), PPAR activation (HX531), and the mitochondrial electron transport chain (VLX-600) repolarized M2 to M1 macrophages or prevented M0-to-M2 polarization in murine bone marrow-derived macrophages. The c-MYC transcription factor is identified as a master regulator of M2 metabolic reprogramming, targetable by nanotherapy-delivered inhibitors in breast cancer models.
c-MYC = master M2 regulatorNanomedicine-Based TAM Targeting
Nanoparticle platforms are extensively described as delivery vehicles for repolarizing agents to TAMs. Approaches include β-cyclodextrin NPs loading TLR agonist R848, nanobody-IMDQ conjugates targeting MMR/CD206, cationic polymers re-educating MDSCs to M1, polyvalent spherical aptamer-engineered macrophages with X-ray-actuated phenotypic transformation, and cellular backpacks attached to macrophages to guide in vivo phenotype. The NIH has highlighted nanomedicine as a key enabling technology for precision immunotherapy.
Cellular backpacks → in vivo phenotype controlMacrophage Depletion & Recruitment Blockade
Macrophage depletion via clodronate liposomes, CSF1R inhibitors, and blockade of monocyte recruitment via CCR2/CCL2 axis inhibitors are established strategies. CSF1R blockade in combination with chemotherapy demonstrated increased intratumoural type I IFN gene expression in cancer patients — providing a direct patient-level pharmacodynamic signal. An engineered CAR-T approach targeting F4/80 depleted TAMs and delayed orthotopic lung tumor growth comparably to PD-1 blockade.
F4/80 CAR-T ≈ PD-1 blockade efficacyCAR-T + Anti-M2 Polarization Inhibitors (Patent)
The University of Pennsylvania patent family describes methods combining recombinant CAR-T cells binding solid tumor antigens with inhibitors of pro-M2 macrophage molecules — including IL-13Rα1 and IL-4Rα antagonists — to prevent TAM polarization to M2 phenotype or reverse M2 TAMs in solid tumors with TAM/MDSC-rich microenvironments. Two distinct jurisdictional filings are present in this dataset (IL and SG), signalling active commercial IP strategy.
UPenn patent — IL + SG jurisdictionsPC1/3 Inhibition — "Drone Macrophage" Strategy
PC1/3 knockdown converts macrophages into constitutively pro-inflammatory "drone macrophages" with enhanced TLR4/TLR9 signaling, NF-κB activation, and anti-tumor cytokine secretion. These can be remotely activated in vivo by systemic TLR ligand administration. Evidence is proteomic and preclinical, from the Inserm PRISM group at Université de Lille — representing a novel cell therapy concept in this dataset.
Remote TLR activation of drone macrophagesKey Target Axes: Mechanisms, Evidence & Translational Stage
A structured view of the principal molecular targets identified across retrieved patent and literature records, with evidence stage and key findings from this dataset.
| Target / Axis | Mechanism | Key Finding (this dataset) | Lead Institution | Stage |
|---|---|---|---|---|
| CSF1R (M-CSFR) | Primary driver of TAM recruitment, differentiation, pro-tumor polarization | Blockade increases intratumoural type I IFN gene expression in cancer patients; IL-34-based CAR-T shows higher affinity than M-CSF-based | Oslo University Hospital; King's College London | Early Clinical |
| IL-4Rα | Shared receptor for IL-4 and IL-13; convergence point for M2 polarization | Dupilumab (FDA-approved) reduces CD206 expression and M2 features in TAMs in prostate cancer models — drug repurposing opportunity | Johns Hopkins School of Medicine | Near-Clinical |
| CD47/SIRPα | "Don't eat me" innate immune checkpoint blocking macrophage phagocytosis | Clinical investigation in AML, MDS, lymphoma; minority of patients respond to monotherapy; PD-1/PD-L1, CD24/SIGLEC-10 also identified | Zhengzhou University | Clinical |
| FcRγ / Megf10 (CAR-M domains) | Intracellular signaling domains triggering antigen-specific phagocytosis in CAR-M constructs | FcRγ = most potent phagocytic and tumor-killing domain; Megf10 also effective; PI3K-recruiting domains modestly enhance engulfment | UCSF; Shenzhen SIAT CAS | Preclinical |
| ACOD1 / KEAP1 | CRISPR-identified metabolic regulators of pro-inflammatory macrophage state in CAR-iMAC platform | ACOD1 KO enhanced polarization persistence, ROS production, phagocytosis, and cytotoxicity in ovarian and pancreatic cancer models | Zhejiang University School of Medicine | Preclinical |
| c-MYC | Transcriptional master regulator of M2 polarization and pro-tumoral gene expression in myeloid cells | Myeloid-conditional Myc KO reduces TAM maturation in vivo; nanotherapy-delivered c-MYC inhibitor prodrug preferentially reached M2 TAMs in breast cancer models | CNIC Madrid; Washington University St. Louis | Preclinical |
| TLR7/8 (R848) | Pattern recognition receptors; agonism drives M1 phenotype conversion | CDNP-R848 controlled tumor growth as monotherapy in mice and protected against tumor rechallenge; nanobody-IMDQ targeting MMR/CD206 achieved cell-specific delivery | Massachusetts General Hospital; VIB Brussels | Preclinical |
| TAM RTKs (Tyro3, Axl, MerTK) | Receptor tyrosine kinases using Gas6 and Protein S as ligands; promote efferocytosis and M2 skewing | Identified as promising therapeutic targets for reversing immunosuppressive macrophage phenotype | Johns Hopkins School of Medicine | Preclinical |
| F4/80 (TAM depletion) | Macrophage surface marker; targeted by CAR-T for TAM depletion | F4/80-targeting CAR-T delayed orthotopic lung tumor growth comparably to PD-1 blockade and extended survival in mice | Mount Sinai | Preclinical |
| miR-223 | Leukocyte-expressed miRNA; knockdown reduces cancer progression | Anti-miR-223-loaded protocells phagocytosed by human macrophages in vitro; extended pro-inflammatory activity | Zebrafish live-imaging studies | Preclinical |
Need real-time target intelligence for your macrophage therapy program?
PatSnap Eureka searches patents and literature simultaneously to surface competitive gaps and white spaces.
Innovation Landscape: Who Is Leading CAR-Macrophage Research?
Innovation activity in this dataset is predominantly literature-driven. Only two patent filings were identified — both from the same assignee — signalling that the commercial IP landscape remains early-stage and open.
University of Pennsylvania — Sole Patent Assignee
The Trustees of the University of Pennsylvania hold the only patents identified in this dataset, with two jurisdictional filings (IL and SG) covering CAR-T combined with anti-M2 molecule inhibitors (IL-13Rα1, IL-4Rα). This signals an active commercial IP strategy around combination immunotherapy involving macrophage polarization modulation in solid tumors.
Zhejiang University — Most Productive Translational Node
Zhejiang University School of Medicine contributed multiple results including the CAR-iMAC iPSC platform, ACOD1 metabolic CRISPR screening, and CAR-M reviews. It represents the most productive single node in this dataset for translational CAR-macrophage innovation, reflecting broader Chinese academic medical center density in this field.
UCSF — Foundational CAR-P Concept
UCSF described the foundational chimeric antigen receptor for phagocytosis (CAR-P) concept, with Megf10 and FcRγ domain screening establishing the mechanistic basis for the entire CAR-M field. Addition of PI3K recruitment domains increased cancer cell engulfment, providing a design framework adopted by subsequent groups.
Massachusetts General Hospital — TLR Agonist Nanoparticle Platform
MGH developed the foundational TLR7/8 agonist nanoparticle polarization platform (CDNP-R848) that drove M1 phenotype conversion in vivo, controlled tumor growth as a monotherapy in mice, and protected against tumor rechallenge — providing robust preclinical proof-of-concept for nanomedicine-delivered repolarization strategies.
From Bench to Bedside: What the Evidence Shows
Retrieved results contain limited but specific clinical translation signals. The strongest direct clinical activity signal in this dataset comes from the life sciences pipeline analysis at Chinese Academy of Medical Sciences: 606 clinical trials targeting TAMs worldwide up to May 2021, including 143 tested products, with explosive growth in the past decade. Most trials were at early phase, with two-thirds employing macrophage-targeting therapies.
CSF1R blockade in cancer patients was shown to increase intratumoural expression of type I IFN-stimulated genes, providing direct patient-level evidence for pharmacodynamic activity as a macrophage-targeting strategy. This was documented by the Platform for Single Cell Genomics, German Center for Neurodegenerative Diseases (2019).
CD47 blockade has reached clinical safety and efficacy studies in AML, MDS, and lymphoma, though retrieved results note that only a minority of patients show significant responses to monotherapy. The FDA has approved several checkpoint inhibitors in these hematological settings, establishing a regulatory pathway for innate immune checkpoint strategies.
Dupilumab (FDA-approved anti-IL-4Rα antibody for atopic dermatitis) demonstrated activity against M2 TAMs in human ex vivo M2 macrophage models and prostate cancer animal models at Johns Hopkins, representing a near-clinical translational signal with an existing safety profile. PatSnap Analytics enables tracking of repurposing opportunities like this across the full patent and regulatory landscape. The European Bioinformatics Institute maintains open drug-target databases that complement this analysis.
CD40 agonists are referenced as showing promise in preliminary clinical trials for macrophage activation, with environmental context (TH1 vs. TH2 TME) noted as influencing therapeutic response.
CAR-Macrophage & TAM Polarization Therapy — Key Questions Answered
Tumor-associated macrophages (TAMs) constitute 30–50% of stromal cells in the tumor microenvironment (TME) across breast, prostate, ovarian, pancreatic, liver, lung, gastric, and colorectal cancers, and up to 50% of the cellular mass within the TME of most solid tumors.
Comparative intracellular domain screening converges on FcRγ as the superior domain for phagocytic activation in CAR-M constructs, with Megf10 also effective. PI3K-recruiting domains modestly enhance engulfment. CAR-M^FcRγ conferred the most potent phagocytic and tumor-killing capacity in comparative studies.
606 clinical trials targeting TAMs were documented worldwide up to May 2021, including 143 tested products, with explosive growth in the past decade. Most trials were at early phase, with two-thirds employing macrophage-targeting therapies.
ACOD1 (aconitate decarboxylase 1) was identified via a CRISPR-based metabolic gene knockout screen in iPSC-derived CAR-macrophages (CAR-iMACs). ACOD1 knockout enhanced polarization persistence, ROS production, phagocytosis, and cytotoxicity in ovarian and pancreatic cancer models, presenting a validated metabolic co-engineering target for next-generation CAR-iMAC design.
CD47 is an innate immune checkpoint blocking macrophage phagocytosis of cancer cells — the so-called "don't eat me" signal. Its blockade is under clinical investigation in AML, MDS, and lymphoma, though only a minority of patients show significant responses to monotherapy. The dataset also identifies PD-1/PD-L1, CD24/SIGLEC-10, and MHC-I/LILRB1 as additional anti-phagocytic checkpoints on myeloid cells.
Dupilumab, an FDA-approved anti-IL-4Rα antibody (for atopic dermatitis), reduces M2 macrophage surface marker expression and CD206 density in TAMs in prostate cancer models, representing a drug repurposing opportunity with an existing clinical safety profile. IL-4Rα is the shared receptor for IL-4 and IL-13, the dominant M2-polarizing cytokines.
Still have questions about the CAR-macrophage pipeline? Let PatSnap Eureka answer them with live patent and literature data.
Ask Eureka About CAR-Macrophage TherapyAccelerate Your Macrophage Therapy Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map the CAR-macrophage pipeline, identify white spaces, and track competitor IP in real time.
References
- Chimeric antigen receptors that trigger phagocytosis — UCSF (2018)
- CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro — Shenzhen SIAT, CAS (2022)
- Metabolic Reprogramming via targeting ACOD1 promotes polarization and anti-tumor activity of human CAR-iMACs — Zhejiang University (2023)
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages — Massachusetts General Hospital (2018)
- Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies — VIB Brussels (2021)
- Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype — Johns Hopkins (2022)
- Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response — Oslo University Hospital (2019)
- CAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor — King's College London (2022)
- Targeting macrophages in hematological malignancies: recent advances and future directions — Zhengzhou University (2022)
- Targeting Tyro3, Axl and MerTK (TAM receptors) — Johns Hopkins School of Medicine (2019)
- In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation — CNIC Madrid (2012)
- Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages in Breast Cancer — Washington University (2020)
- Targeting macrophages with CAR-T cells delays solid tumor progression — Mount Sinai (2021)
- Landscape and perspectives of macrophage-targeted cancer therapy in clinical trials — Chinese Academy of Medical Sciences (2022)
- Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs — University Medical Center Groningen (2021)
- Cellular backpacks for macrophage immunotherapy — Wyss Institute, Harvard (2020)
- Proprotein convertase 1/3 inhibited macrophages: A novel therapeutic based on drone macrophages — Inserm/Université de Lille (2016)
- Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages — Oslo University Hospital (2017)
- World Health Organization — Cancer Global Burden Data
- National Institutes of Health — Nanomedicine and Immunotherapy Research
- U.S. Food and Drug Administration — Checkpoint Inhibitor Approvals
- European Bioinformatics Institute — Drug-Target Databases
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within a targeted dataset and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.